Short Summary
The plaintiff, Novartis AG, seeks to restrain the defendant from manufacturing Pazopanib Hydrochloride, claiming it infringes their Indian patent. The defendant has obtained approval to manufacture the product, raising concerns of imminent patent infringement.
Detailed Summary
In the pharmaceutical world, the gap between a patent expiring and a generic launch can mean billions in lost revenue. But what happens when a generic manufacturer secures regulatory approval to produce a patented drug, and the patent holder has to act fast? This case between Novartis AG and MSN Laboratories Pvt Ltd is a textbook example of how patent owners must move decisively when infringement looms on the horizon.
Novartis AG, a global pharmaceutical leader, held an Indian patent covering Pazopanib Hydrochloride, a critical drug used in cancer treatment. MSN Laboratories Pvt Ltd, an Indian generic pharmaceutical company, obtained approval to manufacture the same compound. This regulatory green light raised immediate red flags for Novartis, as it signaled that MSN was preparing to enter the market with a generic version of a drug still under patent protection in India. Faced with the prospect of imminent infringement, Novartis approached the court seeking an injunction to restrain MSN from manufacturing and launching the product.
Novartis argued that MSN's intended manufacture of Pazopanib Hydrochloride directly infringed its valid and subsisting Indian patent. The mere fact that MSN had secured manufacturing approval, Novartis contended, was evidence enough of an imminent threat to its exclusive rights. On the other side, MSN Laboratories held the position that it had obtained the necessary regulatory clearances to proceed with manufacturing, suggesting it believed it had a legal pathway to produce the drug. The core legal friction centered on whether obtaining manufacturing approval alone was sufficient grounds for an injunction, and whether Novartis could demonstrate a credible threat of infringement that warranted judicial intervention before any actual product launch.
The court ruled in favor of Novartis AG, granting the plaintiff the relief it sought. The decision underscored the court's recognition of the imminent threat posed by MSN's regulatory approval to manufacture a drug still protected by Novartis's patent. By siding with the patent holder, the court reaffirmed that obtaining manufacturing approval for a patented compound constitutes a credible basis for restraining potential infringement, even before the infringing product hits the market.
For founders and IP professionals in the pharmaceutical and biotech space, this case delivers a clear message: regulatory approval is not a shield against patent infringement. If you hold a patent on a compound, monitor generic approvals closely and act the moment a competitor signals intent to manufacture. Conversely, generic manufacturers must conduct thorough freedom-to-operate analyses before pursuing regulatory approvals, because securing a manufacturing license does not guarantee the right to produce a patented product. In the high-stakes pharma arena, speed and vigilance are not optional — they are the price of protecting innovation.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court - Orders. Understanding the court's reasoning in Novartis Ag vs Msn Laboratories Pvt Ltd is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
The North Face Apparel CorpvsController of Patents and Designs
The North Face Apparel Corp challenged the Controller of Patents' refusal of its patent application (No. 202147026139) titled 'Systems and Methods for End-to-End Article Management' before the Madras High Court under Section 117A of the Patents Act, 1970. The Controller had rejected the application citing lack of inventive step over prior art documents D21-D24. The Court held that the Controller erred by dissecting the claims into isolated elements rather than assessing the invention as a whole, and overlooked the use of spectrophotometer and invisible markers for tracking the manufacturing process, which were not disclosed in the cited prior art. The appeal was allowed and the Controller was directed to grant the patent.
Aventose Energy Private LimitedvsThe Assistant Controller of Patents & Designs, Patent Office Chennai
Aventose Energy Private Limited appealed under Section 117A of the Patents Act, 1970 against the refusal of its patent application (No. 202141019671) for a 'System and Method for Operating Automobiles with an Electric Drivetrain' featuring safe mode activation upon fault detection. The Madras High Court found that the Assistant Controller had contradicted the First Examination Report (which accepted novelty) by subsequently holding the invention lacked novelty without giving the applicant an opportunity to be heard. The court further held that the Controller improperly conflated novelty with inventive step under Section 2(1)(ja) and failed to properly analyze the claims against prior art documents D1–D4.
Apex Laboratories Pvt LtdvsElder Lifescience and Ambico Ayurvedic Health Care
Apex Laboratories Pvt Ltd, the prior adopter and registered proprietor of the trademark ZINCOVIT (TM No. 487453 in Class 5) since 1988, sought interim injunction against Elder Lifescience and Ambico Ayurvedic Health Care for using the deceptively similar mark NEO ZINCOVIT. The applicant also claimed copyright infringement of its registered artistic works (A-108878/2014) covering colour scheme, get-up, and layout. The Madras High Court was satisfied that the respondents were attempting to piggyback on the applicant's goodwill and granted interim injunctions on all three applications covering trademark infringement, copyright infringement, and passing off.
Radico Khaitan LimitedvsPicadilly Agro Industries Limited
This Special Leave Petition arose from a judgment dated 29-05-2026 in CS No. 8/2025 passed by the District Judge, Karnal, Haryana, concerning a trademark dispute over the marks 'Cashmere' and 'Kashmyr' used in relation to beer and vodka. The Supreme Court noted that a First Appeal (FAO-COM-11-2026) was already pending before the Division Bench of the Punjab and Haryana High Court, listed for 28.10.2026. The Court disposed of the SLP without adjudicating it on merits, requesting the High Court to pass an appropriate order regarding the ad interim injunction on the scheduled date.
Maharaja Agrasen Technical Educational Society (Regd.)vsMaharaja Agrasen Himalayan Garhwal University
The plaintiff, Maharaja Agrasen Technical Educational Society, filed a suit for permanent injunction against the defendant, Maharaja Agrasen Himalayan Garhwal University, alleging infringement and passing off regarding the use of the words 'Maharaja Agrasen' in the defendant's name. The Delhi High Court had previously granted a restraint order on 10.07.2026. During the pendency of the suit, the parties arrived at a settlement dated 14.09.2026, under which the defendant agreed to change its name through a statutory amendment while being permitted limited transitional use of its existing name. The court recorded the settlement, modified the interim order accordingly, and listed the matter for compliance reporting on 13.07.2027.
Varahi Diamonds And Finance LimitedvsSahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr.
This is a commercial suit filed by Varahi Diamonds And Finance Limited against Sahil Vinay Mehra Trading As Mehra Sons Jewellers & Anr. before the Delhi High Court. The order is primarily procedural, dealing with the registration of the plaint, issuance of summons, directions for filing pleadings, and an interim injunction application. The matter was referred to mediation, with parties directed to appear before the Delhi High Court Mediation and Conciliation Centre.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.